# A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

> **NCT06906380** · — · NOT_YET_RECRUITING · sponsor: **ARCE Therapeutics, Inc.** · enrollment: 49 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia, in Relapsed or Refractory
- MDS (Myelodysplastic Syndrome)

## Interventions

- **OTHER:** Non interventional study

## Key facts

- **NCT ID:** NCT06906380
- **Lead sponsor:** ARCE Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2040-05-30
- **Final completion:** 2040-10-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906380, "A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06906380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*